L-FABP: A novel biomarker of kidney disease

Clinica Chimica Acta

Volumn 445, Issue , 2015, Pages 85-90

  Xu, Yao ^a   Xie, Yuanyuan ^a   Shao, Xinghua ^a   Ni, Zhaohui ^a   Mou, Shan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute kidney injury; Chronic kidney disease; Fatty acid; Liver type fatty acid binding protein

Indexed keywords

BIOLOGICAL MARKER; CONTRAST MEDIUM; FATTY ACID BINDING PROTEIN; LIVER TYPE FATTY ACID BINDING PROTEIN; UNCLASSIFIED DRUG; FABP1 PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; DIABETIC NEPHROPATHY; DISEASE COURSE; EARLY DIAGNOSIS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEART SURGERY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN STRUCTURE; PROTEIN URINE LEVEL; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; TISSUE DISTRIBUTION; ACUTE KIDNEY INJURY; CHEMICAL STRUCTURE; CHEMISTRY; DIABETIC NEPHROPATHIES; GENE EXPRESSION; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; PROTEIN SECONDARY STRUCTURE; RENAL INSUFFICIENCY, CHRONIC;

ACUTE KIDNEY INJURY; BIOMARKERS; DIABETIC NEPHROPATHIES; FATTY ACID-BINDING PROTEINS; GENE EXPRESSION; GLOMERULONEPHRITIS; HUMANS; KIDNEY; MODELS, MOLECULAR; PROGNOSIS; PROTEIN STRUCTURE, SECONDARY; RENAL INSUFFICIENCY, CHRONIC; REPERFUSION INJURY;

EID: 84925944212     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.03.017     Document Type: Review

References (65)

1. McMahon G.M., Waikar S.S. Biomarkers in nephrology: Core Curriculum 2013. Am J Kidney Dis 2013, 62(1):165-178.
2. Waikar S.S., Betensky R.A., Bonventre J.V. Creatinine as the gold standard for kidney injury biomarker studies?. Nephrol Dial Transplant 2009, 24(11):3263-3265.
3. Wasung M.E., Chawla L.S., Madero M. Biomarkers of renal function, which and when?. Clin Chim Acta 2014, 438:350-357.
4. Ockner R.K., Manning J.A., Poppenhausen R.B., Ho W.K. A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues. Science 1972, 177(43):56-58.
5. Kamijo-Ikemori A., Sugaya T., Matsui K., Yokoyama T., Kimura K. Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrol (Carlton) 2011, 16(6):539-544.
6. Yang J., Choi H.M., Seo M.Y., Lee J.Y., Kim K., Jun H., et al. Urine liver-type fatty acid-binding protein predicts graft outcome up to 2years after kidney transplantation. Transplant Proc 2014, 46(2):376-380.
7. Parr S.K., Clark A.J., Bian A., Shintani A.K., Wickersham N.E., Ware L.B., et al. Urinary L-FABP predicts poor outcomes in critically ill patients with early acute kidney injury. Kidney Int 2015, 87(3):640-648.
8. Belcher J.M., Garcia-Tsao G., Sanyal A.J., Thiessen-Philbrook H., Peixoto A.J., Perazella M.A., et al. Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol 2014, 9(11):1857-1867.
9. Yamamoto T., Noiri E., Ono Y., Doi K., Negishi K., Kamijo A., et al. Renal L-type fatty acid binding protein in acute ischemic injury. J Am Soc Nephrol 2007, 18(11):2894-2902.
10. Chmurzyńska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet 2006, 47(1):39-48.
11. Rebecca L.S., Dennis R.P. The human fatty acid-binding protein family: evolutionary divergences and functions. Hum Genom 2011, 5(3):170-191.
12. Michael D.S. Digestion and absorption of dietary triglycerides. The gastrointestinal system: gastrointestinal, nutritional and hepatobiliary physiology 2014, 160-178. E-Publishing Inc, New York. P.S. Leung (Ed.).
13. Sharma A., Yogavel M., Sharma A. Utility of anion and cation combinations for phasing of protein structures. J Struct Funct Genom 2012, 13(3):135-143.
14. Cai J., Lucke C., Chen Z., Qiao Y., Klimtchuk E., Hamilton J.A. Solution structure and backbone dynamics of human liver fatty acid binding protein: fatty acid binding revisited. Biophys J 2012, 102(11):2585-2594.
15. Huang H., McIntosh A.L., Martin G.G., Landrock K.K., Landrock D., Gupta S., et al. Structural and functional interaction of fatty acids with human liver fatty acid-binding protein (L-FABP) T94A variant. FEBS J 2014, 281(9):2266-2283.
16. David A., Sweetser R.O.H., Jeffrey I. Gordon. The metabolic significance of mammalian fatty-acid binding proteins: abundant proteins in search of a function. Annu Rev Nutr 1987, 7:337-359.
17. Petrescu A.D., McIntosh A.L., Storey S.M., Huang H., Martin G.G., Landrock D., et al. High glucose potentiates L-FABP mediated fibrate induction of PPARalpha in mouse hepatocytes. Biochim Biophys Acta 2013, 1831(8):1412-1425.
18. Wolfrum C., Borrmann C.M., Borchers T., Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A 2001, 98(5):2323-2328.
19. Ek-Von Mentzer B.A., Zhang F., Hamilton J.A. Binding of 13-HODE and 15-HETE to phospholipid bilayers, albumin, and intracellular fatty acid binding proteins. Implications for transmembrane and intracellular transport and for protection from lipid peroxidation. J Biol Chem 2001, 276(19):15575-15580.
20. Wang G., Gong Y., Anderson J., Sun D., Minuk G., Roberts M.S., et al. Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology 2005, 42(4):871-879.
21. Fan W., Chen K., Zheng G., Wang W., Teng A., Liu A., et al. Role of liver fatty acid binding protein in hepatocellular injury: effect of CrPic treatment. J Inorg Biochem 2013, 124:46-53.
22. Wang G., Chen Q.M., Minuk G.Y., Gong Y., Burczynski F.J. Enhanced expression of cytosolic fatty acid binding protein and fatty acid uptake during liver regeneration in rats. Mol Cell Biochem 2004, 262(1-2):41-49.
23. Rajaraman G., Burczynski F.J. Effect of dexamethasone, 2-bromopalmitate and clofibrate on L-FABP mediated hepatoma proliferation. J Pharm Pharmacol 2004, 56(9):1155-1161.
24. Chertow G.M., Burdick E., Honour M., Bonventre J.V., Bates D.W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005, 16(11):3365-3370.
25. Uchino S. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818.
26. Tanaka T., Noiri E., Yamamoto T., Sugaya T., Negishi K., Maeda R., et al. Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury. Nephron Exp Nephrol 2008, 108(1):19-26.
27. Siew E.D., Ware L.B., Ikizler T.A. Biological markers of acute kidney injury. J Am Soc Nephrol 2011, 22(5):810-820.
28. Parikh C.R., Butrymowicz I., Yu A., Chinchilli V.M., Park M., Hsu C.Y., et al. Urine stability studies for novel biomarkers of acute kidney injury. Am J Kidney Dis 2014, 63(4):567-572.
29. Basile D.P., Leonard E.C., Beal A.G., Schleuter D., Friedrich J. Persistent oxidative stress following renal ischemia-reperfusion injury increases ANG II hemodynamic and fibrotic activity. Am J Physiol Renal Physiol 2012, 302(11):1494-1502.
30. Abd El-Hamid A.M., Noha N.L. Comparative study on the protective role of vitamin C and L-arginine in experimental renal ischemia reperfusion in adult rats. Int J Phys Pathophysiol Pharmacol 2014, 6(3):153-165.
31. Kwiecien S., Jasons K., Magierowski M., Sliwowski Z., Pajdo R., Brzozowski B., et al. Lipid peroxidation, reactive oxygen species and antioxidatie factors in the pathogenesis of gastric mucosal lesions and mechanism of protection against oxidative stress-indued gastric injury. J Physiol Pharmacol 2014, 65(5):613-622.
32. Iguchi N., Uchiyama A., Ueta K., Sawa Y., Fujino Y. Neutrophil gelatinase-associated lipocalin and liver-type fatty acid-binding protein as biomarkers for acute kidney injury after organ transplantation. J Anesth 2014, 1-7.
33. Yalavarthy R., Edelstein C.L., Teitelbaum I. Acute renal failure and chronic kidney disease following liver transplantation. Hemodial Int 2007, 11(3):S7-S12.
34. Kawai A., Kusaka M., Kitagawa F., Ishii J., Fukami N., Maruyama T., et al. Serum liver-type fatty acid-binding protein predicts recovery of graft function after kidney transplantation from donors after cardiac death. Clin Transpl 2014, 28(6):749-754.
35. Portilla D., Dent C., Sugaya T., Nagothu K.K., Kundi I., Moore P., et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008, 73(4):465-472.
36. Matsui K., Kamijo-Ikemori A., Sugaya T., Yasuda T., Kimura K. Usefulness of urinary biomarkers in early detection of acute kidney injury after cardiac surgery in adults. Circ J 2012, 76(1):213-220.
37. Coca S.G., Garg A.X., Thiessen-Philbrook H., Koyner J.L., Patel U.D., Krumholz H.M., et al. Urinary biomarkers of AKI and mortality 3years after cardiac surgery. J Am Soc Nephrol 2014, 25(5):1063-1071.
38. Krawczeski C.D., Goldstein S.L., Woo J.G., Wang Y., Piyaphanee N., Ma Q., et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol 2011, 58(22):2301-2309.
39. Parikh C.R1., Thiessen-Philbrook H., Garg A.X., Kadiyala D., Shlipak M.G., Koyner J.L., et al. Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol 2013, 8(7):1079-1088.
40. Peco-Antić A., Ivanišević I., Vulićević I., Kotur-Stevuljević J., Ilić S., Ivanišević J., et al. Biomarkers of acute kidney injury in pediatric cardiac surgery. Clin Biochem 2013, 46(13-14):1244-1251.
41. Andreucci M., Faga T., Pisani A., Sabbatini M., Michael A. Acute kidney injury by radiographic contrast media: pathogenesis and prevention. Biomed Res Int 2014, 2014:362725.
42. Curtis L.M., Agarwal A. HOpe for contrast-induced acute kidney injury. Kidney Int 2007, 72(8):907-909.
43. Stacul F., van der Molen A.J., Reimer P., Webb J.A., Thomsen H.S., Morcos S.K., et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011, 21(12):2527-2541.
44. Nakamura T., Sugaya T., Node K., Ueda Y., Koide H. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis 2006, 47(3):439-444.
45. Spector A.A. Fatty acid binding to plasma albumin. J Lipid Res 1975, 16(3):165-179.
46. Hamilton J.A., Era S., Bhamidipati S.P., Reed R.G. Locations of the three primary binding sites for long-chain fatty acids on bovine serum albumin. Proc Natl Acad Sci U S A 1991, 88:2051-2054.
47. Jin K., Norris K., Vaziri N.D. Dysregulation of hepatic fatty acid metabolism in chronic kidney disease. Nephrol Dial Transplant 2013, 28(2):313-320.
48. Zuo N., Suzuki Y., Sugaya T., Osaki K., Kanaguchi Y., Wang L., et al. Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy. Nephrol Dial Transplant 2011, 26(7):2127-2137.
49. Sasaki H., Kamijo-Ikemori A., Sugaya T., Yamashita K., Yokoyama T., Koike J., et al. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract 2009, 112(3):c148-c156.
50. Kamijo-Ikemori A., Sugaya T., Sekizuka A., Hirata K., Kimura K. Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice. Nephrol Dial Transplant 2009, 24(3):788-800.
51. Kamijo A., Kimura K., Sugaya T., Yamanouchi M., Hikawa A., Hirano N., et al. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004, 143:23-30.
52. Ichikawa D., Kamijo-Ikemori A., Sugaya T., Shibagaki Y., Yasuda T., Katayama K., et al. Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation. Am J Physiol Renal Physiol 2014, 306(6):F655-F663.
53. Kamijo-Ikemori A., Sugaya T., Ichikawa D., Hoshino S., Matsui K., Yokoyama T., et al. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta 2013, 424:104-108.
54. Panduru N.M., et al. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2013, 36(7):2077-2083.
55. Kamijo A., Sugaya T., Hikawa A., Yamanouchi M., Hirata Y., Ishimitsu T., et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005, 145(3):125-133.
56. Mou S., Wang Q., Li J., Shi B., Ni Z. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis. Clin Chim Acta 2012, 413(1-2):187-191.
57. Pisani A., Riccio E., Andreucci M., Faga T., Ashour M., Di Nuzzi A., et al. Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy. Biomed Res Int 2013, 2013.
58. Kanaguchi Y., Suzuki Y., Osaki K., Sugaya T., Horikoshi S., Tomino Y. Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis. Nephrol Dial Transplant 2011, 26(11):3465-3473.
59. Schroeder F., Petrescu A.D., Huang H., Atshaves B.P., McIntosh A.L., Martin G.G., et al. Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids 2008, 43(1):1-17.
60. Susantitaphong P., Siribamrungwong M., Doi K., Noiri E., Terrin N., Jaber B.L. Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis. Am J Kidney Dis 2013, 61(3):430-439.
61. Shao X.H., Tian L., Xu W.J., Zhang Z., Wang C., Qi C., et al. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS ONE 2014, 9(1):e84131.
62. Xue W., Xie Y.Y., Wang Q., Xu W.J., Mou S., Ni Z.H. Diagnostic performance of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for acute kidney injury in an obstructive nephropathy patient. Nephrol (Carlton) 2014, 19(4):186-194.
63. Xie Y.Y., Xue W., Shao X.H., Che X.J., Xu W.J., Ni Z.H., et al. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes. PLoS ONE 2014, 9(11):e112865.
64. Xie Y.Y., Xu W.J., Wang Q., Shao X.H., Ni Z.H., Mou S. Urinary excretion of liver-type FABP as a new clinical marker for the progression of obstructive nephropathy. Biomark Med 2014, 8(4):543-556.
65. Manabe K., Kamihata H., Motohiro M., Senoo T., Yoshida S., Iwasaka T. Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury. Eur J Clin Investig 2011, 42(5):557-563.